The European Commission has approved Pfizer's respiratory syncytial virus (RSV) vaccine, ABRYSVO, for the prevention of lower respiratory tract disease caused by RSV. This approval is specifically for adults aged 18 to 59 who are at increased risk of the disease.
This expanded indication in the European Union significantly broadens the target population for ABRYSVO, enhancing its commercial potential in a key international market. The vaccine was previously approved for older adults and pregnant women.
The approval is based on clinical data demonstrating the vaccine's efficacy and safety in this at-risk adult population. This development strengthens Pfizer's vaccine portfolio and its ability to address a wider range of patients susceptible to severe RSV.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.